Related Experiment Video
Updated: Jan 28, 2026

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays
Published on: September 26, 2011
Modelling the dynamics of population viral load measures under HIV treatment as prevention
Ganna Rozhnova1, Marilena Anastasaki1, Mirjam Kretzschmar1,2
1Julius Center for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands.
Insights
Community viral load (CVL) decreases throughout HIV epidemic phases, even as incidence initially rises before antiretroviral treatment (ART) scale-up. Post-ART scale-up, CVL becomes a useful indicator of HIV incidence trends.
Area of Science:
- Epidemiology
- Mathematical Modeling
- Public Health
Background:
- The Centers for Disease Control and Prevention (CDC) established guidelines for population viral load (PVL), community viral load (CVL), and monitored viral load (MVL) in 2011.
- CVL has been utilized to evaluate the impact of antiretroviral treatment (ART) on HIV transmission and as a proxy for HIV incidence.
Purpose of the Study:
- To analyze how aggregate viral load (VL) measures evolve with HIV epidemic phases and identify influencing factors using a mathematical transmission model.
- To assess the correlation between CVL and HIV incidence throughout epidemic progression and ART rollout.
Main Methods:
- A compartmental disease progression and HIV transmission model was developed.
- The model incorporated distinct disease stages with varying viral loads for concentrated (MSM in Western Europe) and generalized (heterosexuals in Sub-Saharan Africa) epidemic scenarios.
Main Results:
- PVL and CVL fluctuate with epidemic phase, while MVL remains constant.
- CVL consistently declines across epidemic stages due to shifts in infected subgroups (undiagnosed, untreated, treated) and disease stages (primary, chronic, AIDS).
- CVL and incidence trends can oppose or coincide; incidence rises as CVL falls before significant ART scale-up, after which CVL effectively indicates incidence changes. HIV transmission during ART scale-up is driven by undiagnosed/untreated individuals, with new infections decreasing as ART coverage increases.
Conclusions:
- CVL dynamics are influenced by the interplay of infected subgroups and disease progression.
- While CVL does not fully capture transmission from undiagnosed individuals, its decline reflects increased ART coverage.
- Current epidemic phases in the model exhibit declining trends in both CVL and incidence.
Abstract:
In 2011 the Centers for Disease Control and Prevention (CDC) published guidelines for the use of population viral load (PVL), community viral load (CVL) and monitored viral load (MVL), defined as the average viral load (VL) of all HIV infected individuals in a population, of all diagnosed individuals, and of all individuals on antiretroviral treatment (ART), respectively. Since then, CVL has been used to assess the effectiveness of ART on HIV transmission and as a proxy for HIV incidence. The first objective of this study was to investigate how aggregate VL measures change with the HIV epidemic phase and the drivers behind these changes using a mathematical transmission model. Secondly, we aimed to give some insight into how well CVL correlates with HIV incidence during the course of the epidemic and roll out of ART. We developed a compartmental model for disease progression and HIV transmission with disease stages that differ in viral loads for epidemiological scenarios relevant to a concentrated epidemic in a population of men who have sex with men (MSM) in Western Europe (WE) and to a generalized epidemic in a heterosexual population in Sub-Saharan Africa (SSA). The model predicts that PVL and CVL change with the epidemic phase, while MVL stays constant. These dynamics are linked to the dynamics of infected subgroups (undiagnosed, diagnosed untreated and treated) in different disease stages (primary, chronic and AIDS). In particular, CVL decreases through all epidemic stages: before ART, since chronic population builds up faster than AIDS population and after ART, due to the build-up of treated population with low VL. The trends in CVL and incidence can be both opposing and coinciding depending on the epidemic phase. Before ART is scaled up to sufficiently high levels, incidence increases while CVL decreases. After this point, CVL is a useful indicator of changes in HIV incidence. The model predicts that during the ART scale-up HIV transmission is driven by undiagnosed and diagnosed untreated individuals, and that new infections decline due to the increase in the number of treated. Although CVL is not able to capture the contribution of undiagnosed population to HIV transmission, it declines due to the increase of people on ART too. In the scenarios described by our model, the present epidemic phase corresponds to declining trends in CVL and incidence.
Related Concept Videos
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Population Growth
Viral Recombination
Models of Health Promotion and Illness Prevention II
The agent-host-environment model states that disease results...
Viral Mutations
Coronary Artery Disease IV: Preventive Measures

